{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:51:00Z","timestamp":1792183860596,"version":"4.4.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Medicine Open"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ajmo.2025.100114","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T04:07:07Z","timestamp":1755749227000},"page":"100114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["GLP-1 Receptor Agonists Initiation and Risk of Acute Pancreatitis and Pancreatic Cancer: A Real-World Comparative Study"],"prefix":"10.1016","volume":"14","author":[{"given":"Omar","family":"Faour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moheb","family":"Boktor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-2407","authenticated-orcid":false,"given":"Hanford","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3003-1759","authenticated-orcid":false,"given":"Mustafa","family":"Kinaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishak A","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ajmo.2025.100114_bib0001","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3949\/ccjm.89a.21110","article-title":"The role of GLP-1 receptor agonists in managing type 2 diabetes","volume":"89","author":"Nachawi","year":"2022","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.ajmo.2025.100114_bib0002","article-title":"GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.ajmo.2025.100114_bib0003","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ajmo.2025.100114_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.ajmo.2025.100114_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"10.1016\/j.ajmo.2025.100114_bib0006","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.ajmo.2025.100114_bib0007","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4158\/EP11290.OR","article-title":"Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting","volume":"18","author":"Lando","year":"2012","journal-title":"Endocr Pract"},{"issue":"11","key":"10.1016\/j.ajmo.2025.100114_bib0008","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1016\/j.celrep.2016.11.051","article-title":"Glucagon-like peptide 1 receptor signaling in acinar cells causes growth-dependent release of pancreatic enzymes","volume":"17","author":"Wewer Albrechtsen","year":"2016","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.ajmo.2025.100114_bib0009","doi-asserted-by":"crossref","first-page":"966","DOI":"10.2337\/dc16-2747","article-title":"Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial","volume":"40","author":"Steinberg","year":"2017","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ajmo.2025.100114_bib0010","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2337\/dc16-0984","article-title":"Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide","volume":"40","author":"Nauck","year":"2017","journal-title":"Diabetes Care"},{"issue":"19","key":"10.1016\/j.ajmo.2025.100114_bib0011","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.ajmo.2025.100114_bib0012","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajmo.2025.100114_bib0013","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabet Endocrinol"},{"issue":"2","key":"10.1016\/j.ajmo.2025.100114_bib0014","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12020-019-02055-z","article-title":"GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials","volume":"66","author":"Cao","year":"2019","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.ajmo.2025.100114_bib0015","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.ajmo.2025.100114_bib0016","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.ajmo.2025.100114_bib0017","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/dom.12926","article-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials","volume":"19","author":"Monami","year":"2017","journal-title":"Diabetes Obes Metab."},{"issue":"7","key":"10.1016\/j.ajmo.2025.100114_bib0018","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1177\/10600280231205490","article-title":"Risk of pancreatitis with incretin therapies versus thiazolidinediones in the Veterans Health Administration","volume":"58","author":"Wilhite","year":"2024","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.ajmo.2025.100114_bib0019","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4093\/dmj.2024.0105","article-title":"Use of glucagon-like peptide-1 receptor agonists does not increase the risk of cancer in patients with type 2 diabetes mellitus","volume":"49","author":"Kim","year":"2025","journal-title":"Diabetes Metab J"},{"issue":"1","key":"10.1016\/j.ajmo.2025.100114_bib0020","doi-asserted-by":"crossref","first-page":"T43","DOI":"10.1530\/JOE-13-0577","article-title":"Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology?","volume":"221","author":"Lamont","year":"2014","journal-title":"J Endocrinol."},{"issue":"5","key":"10.1016\/j.ajmo.2025.100114_bib0021","doi-asserted-by":"crossref","first-page":"F77","DOI":"10.1530\/ERC-12-0111","article-title":"GLP1 and cancer: friend or foe?","volume":"19","author":"Vangoitsenhoven","year":"2012","journal-title":"Endocr Relat Cancer."},{"issue":"3","key":"10.1016\/j.ajmo.2025.100114_bib0022","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11096-023-01556-2","article-title":"Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis","volume":"45","author":"Cao","year":"2023","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.ajmo.2025.100114_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107981","article-title":"Pancreatitis and pancreatic cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive and updated meta-analysis of randomized controlled trials","volume":"159","author":"Dicembrini","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"10.1016\/j.ajmo.2025.100114_bib0024","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.clinthera.2024.06.015","article-title":"Pancreatitis and pancreatic cancer risk among patients with type 2 diabetes receiving dipeptidyl peptidase 4 inhibitors: an updated meta-analysis of randomized controlled trials","volume":"46","author":"Tuersun","year":"2024","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.ajmo.2025.100114_bib0025","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/dom.12605","article-title":"Use of incretin agents and risk of pancreatic cancer: a population-based cohort study","volume":"18","author":"Knapen","year":"2016","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.ajmo.2025.100114_sbref0026","year":"2008"},{"key":"10.1016\/j.ajmo.2025.100114_bib0027","article-title":"VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives","year":"2023","journal-title":"U.S. Department of Veterans Affairs"},{"issue":"4","key":"10.1016\/j.ajmo.2025.100114_bib0028","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"issue":"7","key":"10.1016\/j.ajmo.2025.100114_bib0029","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol."},{"issue":"7","key":"10.1016\/j.ajmo.2025.100114_bib0030","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jama.2023.13872","article-title":"Patents and regulatory exclusivities on GLP-1 receptor agonists","volume":"330","author":"Alhiary","year":"2023","journal-title":"JAMA."},{"issue":"1","key":"10.1016\/j.ajmo.2025.100114_bib0031","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pan.2015.05.465","article-title":"Clinical use of GLP-1 agonists and DPP4 inhibitors","volume":"16","author":"Tuch","year":"2016","journal-title":"Pancreatology"},{"issue":"1","key":"10.1016\/j.ajmo.2025.100114_bib0032","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/EDE.0000000000001541","article-title":"Validation of acute pancreatitis among adults in an integrated healthcare system","volume":"34","author":"Floyd","year":"2023","journal-title":"Epidemiology"},{"key":"10.1016\/j.ajmo.2025.100114_bib0033","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2147\/CLEP.S139895","article-title":"Positive predictive values of ICD-10 codes to identify incident acute pancreatitis and incident primary malignancy in the Scandinavian national patient registries among women with postmenopausal osteoporosis","volume":"9","author":"Munch","year":"2017","journal-title":"Clin Epidemiol"},{"issue":"37","key":"10.1016\/j.ajmo.2025.100114_bib0034","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.3748\/wjg.v25.i37.5619","article-title":"Accuracy of an administrative database for pancreatic cancer by international classification of disease 10(th) codes: a retrospective large-cohort study","volume":"25","author":"Hwang","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.ajmo.2025.100114_bib0035","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.ajmo.2025.100114_bib0036","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/gerona\/gly232","article-title":"The burden of frailty among U.S. veterans and its association with mortality, 2002-2012","volume":"74","author":"Orkaby","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci."},{"key":"10.1016\/j.ajmo.2025.100114_bib0037","article-title":"Clinical Classifications Software (CCS) for ICD-9-CM: databases and related tools from the Healthcare Cost and Utilization Project (HCUP)","author":"Elixhauser","year":"2015","journal-title":"U.S. Agency for Healthcare Research and Quality"},{"issue":"4","key":"10.1016\/j.ajmo.2025.100114_bib0038","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/1475-6773.00165","article-title":"Improved comorbidity adjustment for predicting mortality in Medicare populations","volume":"38","author":"Schneeweiss","year":"2003","journal-title":"Health Serv Res."},{"issue":"6","key":"10.1016\/j.ajmo.2025.100114_bib0039","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol."},{"issue":"4","key":"10.1016\/j.ajmo.2025.100114_bib0040","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1536867X0200200403","article-title":"Estimation of average treatment effects based on propensity scores","volume":"2","author":"Becker","year":"2002","journal-title":"Stata J"},{"key":"10.1016\/j.ajmo.2025.100114_bib0041","series-title":"PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing","author":"Edwin","year":"2003"},{"issue":"18","key":"10.1016\/j.ajmo.2025.100114_bib0042","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ajmo.2025.100114_bib0043","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr."},{"issue":"7","key":"10.1016\/j.ajmo.2025.100114_bib0044","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial","volume":"314","author":"Davies","year":"2015","journal-title":"Jama"},{"issue":"10278","key":"10.1016\/j.ajmo.2025.100114_bib0045","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ajmo.2025.100114_bib0046","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50408","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes","volume":"7","author":"Dankner","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.ajmo.2025.100114_bib0047","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.ajmo.2025.100114_bib0048","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0895-4356(01)00510-8","article-title":"Calculating the \"number needed to be exposed\" with adjustment for confounding variables in epidemiological studies","volume":"55","author":"Bender","year":"2002","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.ajmo.2025.100114_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102696","article-title":"Glucagon-like peptide 1-receptor agonists and A1c: good for the heart but less so for the eyes?","volume":"17","author":"Albert","year":"2023","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"10.1016\/j.ajmo.2025.100114_bib0050","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40620-023-01858-8","article-title":"Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data","volume":"37","author":"Brockmeyer","year":"2024","journal-title":"J Nephrol"},{"issue":"10","key":"10.1016\/j.ajmo.2025.100114_bib0051","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00592-022-01917-9","article-title":"Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials of new antidiabetic drugs: a meta-analysis of digitalized individual patient data","volume":"59","author":"Kuss","year":"2022","journal-title":"Acta Diabetol"},{"issue":"4","key":"10.1016\/j.ajmo.2025.100114_bib0052","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/1077558715617382","article-title":"Do Veterans Health Administration enrollees generalize to other populations?","volume":"73","author":"Wong","year":"2016","journal-title":"Med Care Res Rev."},{"issue":"1","key":"10.1016\/j.ajmo.2025.100114_bib0053","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/s41598-017-19055-6","article-title":"Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis","volume":"8","author":"Pinto","year":"2018","journal-title":"Sci Rep"}],"container-title":["American Journal of Medicine Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667036425000287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667036425000287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T04:19:59Z","timestamp":1765253999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667036425000287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":53,"alternative-id":["S2667036425000287"],"URL":"https:\/\/doi.org\/10.1016\/j.ajmo.2025.100114","relation":{},"ISSN":["2667-0364"],"issn-type":[{"value":"2667-0364","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 Receptor Agonists Initiation and Risk of Acute Pancreatitis and Pancreatic Cancer: A Real-World Comparative Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Medicine Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajmo.2025.100114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100114"}}